Cyprian Gardine is an Endocrinology/Metabolic physician. OpenAlex indexes 5 publications with 612 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Lafayette Ave SE
Ste 2045
Grand Rapids, MI 495034692
Telephone
616-685-3098Provider last certified this registry record 15 Dec 2021.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Dexcom, Inc.Program year20232 payments
- Dexcom, Inc.Program year20221 payment
- Xeris Pharmaceuticals, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
48%Insulin Analog14%Lantus Solostar32%Humalog Kwikpen U-10015%Toujeo Solostar13%Novolog Flexpen10%Humalog7%Lantus7%Novolog5%Toujeo Max Solostar4%Tresiba Flextouch U-2004%Tresiba Flextouch U-1003%Basaglar Kwikpen U-1002%Part D<11 patientsGLP-1 receptor agonist11%Trulicity39%Mounjaro31%Ozempic30%Part D≥47 patients+ 9 more classes in this area
Hormonal (systemic)
34.8%l-Thyroxine26.3%Levothyroxine Sodium90%Synthroid8%Levoxyl2%Part D<11 patientsThyroid Hormone Synthesis Inhibitor4.1%Methimazole100%Part D≥48 patients+ 5 more classes in this area
Cardiovascular
7.4%Statin3.4%Atorvastatin Calcium45%Pravastatin Sodium18%Simvastatin16%Rosuvastatin Calcium12%Lovastatin9%Part D<11 patientsACE inhibitor1.4%Lisinopril100%Part D≥18 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Multiple fragments of human TG are capable of inducing oral tolerance to whole human TG
Journal of Endocrinological Investigation
2003 - Relation of three polymorphisms of the CTLA-4 gene in patients with Graves’ disease
Journal of Endocrinological Investigation
2002 - PROSPECTS FOR TOLERIZATION TO THYROID AUTOANTIGENS
Medical Entomology and Zoology
1997
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”